AstraZeneca makes and sells prescription drugs for serious illnesses like cancer and heart disease, similar to how a baker makes and sells specialized cakes.
The company's revenue comes from selling its patented medicines. In 2024, it generated USD 54.07B in revenue with a net profit margin of 13.01%.
AstraZeneca's patents on its drugs prevent competitors like Pfizer and Novartis from easily copying its products. However, patent expirations and the rise of generics pose a threat.
Key events, in time order
IDMC finds unlikely to meet key survival goals; other lung cancer trials continue
Reuters cites senior source denying merger talks, saying never a deal, ending prior speculation.
Preliminary merger discussions could create one of the largest drugmakers ever, with antitrust scrutiny and strategy questions in focus.
Citi lifts PT to 17,800p while Deutsche repeats sell at 11,500p, showing pipeline divergence
Executive says new drug pricing adapting to US most-favored-nation policy, impacting future pricing.
EU clears Etcamah in combination with a CDK4/6 inhibitor for first-line advanced ER-positive breast cancer
Up to $425M deal for Neurimmune's royalty interest
Baader Bank opens new position, Andra AP fonden buys $46.6M, DekaBank boosts, Boston Common trims
New today: $600M upfront, up to $1.5B total, global rights.
Total revenue grew 8% in Q1 2026, with core EPS growing 5% to $2.58
None yet
None yet
The user is tracking weekly changes in stock holdings, noting a decrease in $AZN. The discussion revolves around personal portfolio adjustments and the lack of M&A activity impacting certain stocks.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
